Dhiren Patel, PharmD, CDCES, BC-ADM, BCACP

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.